{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:21:08Z","timestamp":1791390068769,"version":"4.3.3"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["U54DA037842"],"award-info":[{"award-number":["U54DA037842"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.drugalcdep.2020.108482","type":"journal-article","created":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T11:47:09Z","timestamp":1610106429000},"page":"108482","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Lorcaserin treatment for extended-release naltrexone induction and retention for opioid use disorder individuals: A pilot, placebo-controlled randomized trial"],"prefix":"10.1016","volume":"219","author":[{"given":"Frances R.","family":"Levin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Pavlicova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0466-052X","authenticated-orcid":false,"given":"C. Jean","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cale","family":"Basaraba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9106-2818","authenticated-orcid":false,"given":"Amy L.","family":"Mahony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasir","family":"Naqvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Bisaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2020.108482_bib0005","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association (APA)","year":"2013"},{"key":"10.1016\/j.drugalcdep.2020.108482_bib0010","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jsat.2014.01.005","article-title":"A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence","volume":"46","author":"Bisaga","year":"2014","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2020.108482_bib0015","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.drugalcdep.2015.05.013","article-title":"The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone","volume":"154","author":"Bisaga","year":"2015","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2020.108482_bib0020","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.drugalcdep.2018.02.023","article-title":"Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: a phase 3 randomized trial","volume":"187","author":"Bisaga","year":"2018","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2020.108482_bib0025","doi-asserted-by":"crossref","first-page":"107859","DOI":"10.1016\/j.drugalcdep.2020.107859","article-title":"Effects of lorcaserin on oxycodone self-administration and subjective responses in participants with opioid use disorder","volume":"208","author":"Brandt","year":"2020","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2020.108482_bib0030","series-title":"Drug Overdose Deaths","author":"Centers for Disease Control and Prevention (CDC)","year":"2020"},{"key":"10.1016\/j.drugalcdep.2020.108482_bib0035","doi-asserted-by":"crossref","first-page":"37","DOI":"10.15585\/mmwr.mm6802a3","article-title":"Overdose deaths involving fentanyl and fentanyl analogs - New York City, 2000-2017. MMWR morb","volume":"68","author":"Colon-Berezin","year":"2019","journal-title":"Mortal. Wkly."},{"key":"10.1016\/j.drugalcdep.2020.108482_bib0040","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.neuropharm.2013.06.030","article-title":"Serotonin at the nexus of impulsivity and cue reactivity in cocaine addiction","volume":"76","author":"Cunningham","year":"2014","journal-title":"Neuropharmacology."},{"key":"10.1016\/j.drugalcdep.2020.108482_bib0045","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/ijerph8010015","article-title":"Blocked randomization with randomly selected block sizes","volume":"8","author":"Efrid","year":"2011","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.drugalcdep.2020.108482_bib0050","series-title":"FDA Requests the Withdrawal of the Weight-loss Drug Belviq, Belviq-xr (lorcaserin) From the Market","author":"Federal Drug Administration (FDA)","year":"2020"},{"key":"10.1016\/j.drugalcdep.2020.108482_bib0055","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3109\/00952998709001515","article-title":"Two new rating scales for opiate withdrawal","volume":"13","author":"Handelsman","year":"1987","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.drugalcdep.2020.108482_bib0060","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.drugalcdep.2012.08.007","article-title":"Assessment of riboflavin as a tracer substance: comparison of a qualitative to a quantitative method of riboflavin measurement","volume":"128","author":"Herron","year":"2013","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2020.108482_bib0065","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/add.12333","article-title":"Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial","volume":"109","author":"Hser","year":"2014","journal-title":"Addiction."},{"key":"10.1016\/j.drugalcdep.2020.108482_bib0070","doi-asserted-by":"crossref","first-page":"157","DOI":"10.15288\/jsas.2005.s15.157","article-title":"The COMBINE SAFTEE: a structured instrument for collecting adverse events adapted for clinical studies in the alcoholism field","volume":"15","author":"Johnson","year":"2005","journal-title":"J. Stud. Alcohol Suppl."},{"key":"10.1016\/j.drugalcdep.2020.108482_bib0075","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.2105\/AJPH.2015.302664","article-title":"National and state treatment need and capacity for opioid agonist medication-assisted treatment","volume":"105","author":"Jones","year":"2015","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.drugalcdep.2020.108482_bib0080","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0140-6736(03)12600-1","article-title":"1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial","volume":"361","author":"Kakko","year":"2003","journal-title":"Lancet."},{"key":"10.1016\/j.drugalcdep.2020.108482_bib0085","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/ajhp\/zxz105","article-title":"Medications for management of opioid use disorder","volume":"76","author":"Koehl","year":"2019","journal-title":"Am. J. Health. Syst. Pharm."},{"key":"10.1016\/j.drugalcdep.2020.108482_bib0090","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejphar.2018.09.025","article-title":"Lorcaserin decreases the reinforcing effects of heroin, but not food, in rhesus monkeys","volume":"840","author":"Kohut","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2020.108482_bib0095","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.drugalcdep.2020.108482_bib0100","series-title":"Measuring Alcohol Consumption: Psychosocial and Biochemical Methods","author":"Litten","year":"1992"},{"key":"10.1016\/j.drugalcdep.2020.108482_bib0105","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.drugalcdep.2014.02.002","article-title":"Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial","volume":"138","author":"Mannelli","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2020.108482_bib0110","doi-asserted-by":"crossref","first-page":"7832752","DOI":"10.1155\/2019\/7832752","article-title":"Factors influencing buprenorphine prescribing among physicians in New York State","volume":"2019","author":"Marino","year":"2019","journal-title":"J. Addict."},{"key":"10.1016\/j.drugalcdep.2020.108482_bib0115","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jsat.2017.07.001","article-title":"Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population","volume":"85","author":"Morgan","year":"2018","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2020.108482_bib0120","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drugalcdep.2019.02.031","article-title":"Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort","volume":"200","author":"Morgan","year":"2019","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2020.108482_bib0125","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1021\/acschemneuro.6b00413","article-title":"Lorcaserin suppresses oxycodone self-administration and relapse vulnerability in rats","volume":"8","author":"Neelakantan","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.drugalcdep.2020.108482_bib0130","series-title":"Unintentional Drug Poisoning (overdose) Deaths in New York City, 2000 to 2017","author":"Nolan","year":"2018"},{"key":"10.1016\/j.drugalcdep.2020.108482_bib0135","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0740-5472(02)00301-X","article-title":"Behavioral naltrexone therapy: an integrated treatment for opiate dependence","volume":"23","author":"Rothenberg","year":"2002","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.drugalcdep.2020.108482_bib0140","first-page":"944","article-title":"Lorcaserin for smoking cessation and associated weight gain: a randomized 12-Week clinical trial","volume":"19","author":"Shanahan","year":"2017","journal-title":"Nicotine Tob. Res."},{"issue":"Suppl 20","key":"10.1016\/j.drugalcdep.2020.108482_bib0145","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2020.108482_bib0150","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/clpt.2011.20","article-title":"Evaluation of the abuse potential of lorcaserin, a serotonin 2C (5-HT2C) receptor agonist, in recreational polydrug users","volume":"89","author":"Shram","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.drugalcdep.2020.108482_bib0155","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1080\/00952990.2019.1700265","article-title":"A week-long outpatient induction onto XR-naltrexone in patients with opioid use disorder","volume":"46","author":"Sibai","year":"2020","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.drugalcdep.2020.108482_bib0160","doi-asserted-by":"crossref","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ."},{"key":"10.1016\/j.drugalcdep.2020.108482_bib0165","series-title":"Key Substance Use and Mental Health Indicators in the United States: Results From the 2018 National Survey on Drug Use and Health (HHS Publication No. PEP19-5068, NSDUH Series H-54). Rockville, MD: Center for Behavioral Health Statistics and Quality","author":"Substance Abuse and Mental Health Services Administration (SAMHSA)","year":"2019"},{"key":"10.1016\/j.drugalcdep.2020.108482_bib0170","series-title":"SAMHSA's 2018 National Survey on Drug Use and Health (NSDUH)","author":"Substance Abuse and Mental Health Services Administration (SAMHSA)","year":"2019"},{"key":"10.1016\/j.drugalcdep.2020.108482_bib0175","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1176\/appi.ajp.2016.16050548","article-title":"Long-acting injectable naltrexone induction: a randomized trial of outpatient opioid detoxification with naltrexone versus buprenorphine","volume":"174","author":"Sullivan","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2020.108482_bib0180","doi-asserted-by":"crossref","first-page":"107848","DOI":"10.1016\/j.drugalcdep.2020.107848","article-title":"Lorcaserin maintenance fails to attenuate heroin vs. food choice in rhesus monkeys","volume":"208","author":"Townsend","year":"2020","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2020.108482_bib0185","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/02791072.2003.10400007","article-title":"The Clinical Opiate Withdrawal Scale (COWS)","volume":"35","author":"Wesson","year":"2003","journal-title":"J. Psychoactive Drugs"},{"key":"10.1016\/j.drugalcdep.2020.108482_bib0190","doi-asserted-by":"crossref","first-page":"290","DOI":"10.15585\/mmwr.mm6911a4","article-title":"Drug and opioid-involved overdose deaths\u2014United States, 2017\u20132018","volume":"69","author":"Wilson","year":"2020","journal-title":"MMWR Morb. Mortal. Wkly."},{"key":"10.1016\/j.drugalcdep.2020.108482_bib0195","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.neulet.2015.09.013","article-title":"Activation of serotonin 5-HT2C receptor suppresses behavioral sensitization and naloxone-precipitated withdrawal symptoms in heroin-treated mice","volume":"607","author":"Wu","year":"2015","journal-title":"Neurosci. Lett."}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871620306475?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871620306475?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T22:28:57Z","timestamp":1732314537000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871620306475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":39,"alternative-id":["S0376871620306475"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108482","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lorcaserin treatment for extended-release naltrexone induction and retention for opioid use disorder individuals: A pilot, placebo-controlled randomized trial","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108482","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108482"}}